Received: 10 October 2018
Accepted: 11 July 2019
First Online: 19 July 2019
Ethics approval and consent to participate
: The STOP-Uveitis clinical trial was conducted in compliance with the US Code of Federal Regulations Title 21, the Declaration of Helsinki, and the Harmonized Tripartite Guidelines for Good Clinical Practice (1996). The study was approved by local institutional review boards for selected sites and by a central review board for others. Signed informed consent was obtained from all the participants of the study<b>.</b>
: Not applicable
: YJS has received research support from Astellas, Genentech, and Optovue and serves on the Scientific Advisory Board for Genentech/Roche, Optos, and Regeneron.QDN is a recipient of a Physician Scientist Award from Research to Prevent Blindness, New York, NY, and serves on the Scientific Advisory Board for AbbVie, Bayer, Genentech, Regeneron, and Santen, among others. QDN also chaired the Steering Committee for the RISE and RIDE studies and was on the Steering Committee for the VISTA Study, and other studies sponsored by Genentech and Regeneron.DVD is a consultant for Allergan, Genentech, Regeneron, and Santen and she has received research support from Genentech, Regeneron, and Santen. DVD also chaired the Steering Committee for the VISTA Study.The other authors declare that they have no competing interests.